The burgeoning landscape of therapy for excess body fat and type 2 metabolic disorder is currently witnessing considerable attention surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant distinctions in their pharmacological profiles and clinical trial results are emerging. Retatrut